rttnews.com
Cure8 news brief
Why This Matters
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for patients and clinicians.
Who Should Pay Attention
Patients on or considering infliximab (including those switching from IV to subcutaneous), gastroenterologists and IBD clinicians, and researchers studying biologic formulations and biomarkers in IBD.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
Celltrion will present two new analyses at ACG 2026: a post-hoc look at patients who restarted subcutaneous infliximab after an interruption in intravenous therapy, and a pooled, propensity-matched comparison of subcutaneous versus intravenous infliximab in ileal/ileocolonic Crohn's disease.
The interruption analysis evaluated prior anti-drug antibody status, timing between last IV dose and restart of subcutaneous therapy, and tracked clinical response, serum drug levels, fecal calprotectin, and CRP over time.
The pooled Crohn's analysis compared clinical remission and endoscopic outcomes at Week 54 between matched groups receiving subcutaneous versus IV infliximab.
Keep In Mind
Presentations are analyses to be delivered at ACG 2026; they appear to be post-hoc and pooled/propensity-matched analyses. Such study types can suggest hypotheses but typically need more detailed peer-reviewed reporting to confirm applicability.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationrttnews.com
AuthorsRTTNews Staff Writer
Indexed viaBing News
Source typeWeb article
PublishedOct 11, 2026, 1:37 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Intestinal ultrasound: a non-invasive alternative to monitor and predict biologic treatment persistence in patients with inflammatory bowel disease.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
Early Prediction of Primary Non-Response to Infliximab in Crohn's Di - Dove Medical Press
Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.
Dose escalation for secondary loss of response in inflammatory bowel disease: 3-year outcomes and treatment persistence.
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...